The Optimal Dose of Amobarbital in the Wada Test for the Presurgical Evaluation of Patients With Temporal Lobe Epilepsy.

Abstract:

OBJECTIVE:The use of amobarbital in the Wada test varied between epilepsy centers, with no unified dosing or protocols available in the literature to standardize its use. We aimed to determine the dose of amobarbital in the presurgical evaluations of patients with temporal lobe epilepsy. METHODS:A retrospective study of patients with temporal lobe epilepsy seen between January 2004 and December 2018 in King Faisal Specialist Hospital and Research Centre in Jeddah, Saudi Arabia, was conducted, and those who successfully underwent a Wada test were studied. A neuropsychologist or a neurologist will assess the memory and language, using standardized testing. RESULTS:A total of 90 patients were studied. The mean age was 30 years (range, 16-52 years), where 49 (57%) of them were men. All patients had a routine neurological examination, including language and memory. The average dose of amobarbital given was 10.1.1 mg (range, 65.7-150 mg). There was no statistical difference between the dosing given to patients who passed or failed the memory testing (101.4 mg vs 94.7 mg, P = 0.1). Multivariate regression analysis showed that amobarbital dose needed an adjustment to patient's weight only for those older than 30 years, (P < 0.05; 95% confidence interval, 0.1-0.5), where an increase in the dose by 0.3 mg·kg·y was required to execute Wada test successfully. CONCLUSION:It was only the patient's age that could influence the modification of Amobarbital dose in the Wada test, yet establishing a universal protocol is challenging because of the lack of well-defined dose determinants.

journal_name

Clin Neuropharmacol

authors

Bajammal S,Babtain F,Alqadi K,Baeesa S,Kurdi K,Madani N,Al Said Y

doi

10.1097/WNF.0000000000000411

subject

Has Abstract

pub_date

2020-11-01 00:00:00

pages

185-190

issue

6

eissn

0362-5664

issn

1537-162X

journal_volume

43

pub_type

杂志文章
  • Metabolic and hormonal effects of dexfenfluramine on stress situations.

    abstract::Chronic treatment of rats with dexfenfluramine decreased the concentrations of circulating corticosterone, fatty acid, glycerol, and triacylglycerol after feeding a test load of fructose. It also decreased the rise in adrenalin in the blood of rats that were anaesthetized with urethane. These effects of dexfenfluramin...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Brindley DN

    更新日期:1988-01-01 00:00:00

  • Polyradiculoneuritis after botulinum toxin therapy for cervical dystonia.

    abstract::A 40-year-old man with cervical dystonia developed an acute inflammatory demyelinating polyradiculoneuritis after botulinum toxin type A treatment. Some cases of idiopathic brachial plexopathy and polyradiculoneuritis have been reported to date. Although a causal relationship is not firmly established, the clinical te...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200007000-00012

    authors: Burguera JA,Villaroya T,López-Alemany M

    更新日期:2000-07-01 00:00:00

  • The nitric oxide pathway: potential implications for treatment of neuropsychiatric disorders.

    abstract::The freely diffusible gaseous compound nitric oxide (NO) has recently been discovered to be an important cellular messenger in many organ systems throughout the body. The importance of NO as an intermediary in cell communication in the brain is highlighted by the fact that the excitatory amino acid glutamate, the most...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Karatinos J,Rosse RB,Deutsch SI

    更新日期:1995-12-01 00:00:00

  • Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.

    abstract::Deprenyl, a selective inhibitor of monoamine oxidase, type B, which is free of the "tyramine effect," may ameliorate symptom fluctuations in advanced Parkinson's disease (PD). We randomized 96 patients with marked symptom fluctuations at three centers to receive either deprenyl 5 mg b.i.d. or placebo in parallel fashi...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-198802000-00004

    authors: Golbe LI,Lieberman AN,Muenter MD,Ahlskog JE,Gopinathan G,Neophytides AN,Foo SH,Duvoisin RC

    更新日期:1988-02-01 00:00:00

  • Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.

    abstract::Male albino rats received a stereotaxic injection of 6-hydroxydopamine (6-OHDA) into the right substantia nigra. Animals demonstrating contralateral rotations 2 weeks postoperatively with apomorphine (0.5 mg/kg i.p.) were treated with L-Dopa (55 mg/kg i.p.), bromocriptine (2 mg/kg i.p.), or polyethylene glycol (vehicl...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Schneider MB,Murrin LC,Pfeiffer RF,Deupree JD

    更新日期:1984-01-01 00:00:00

  • Paroxetine-associated hypereosinophilia may clinically resemble a panic attack.

    abstract::Hypereosinophilia is asymptomatic but can induce organ damage, which may cause neurological system abnormalities. We recently encountered a 29-year-old woman with depressive episodes who had eosinophilia as well as hyperventilation attacks, tremor, insomnia, and arthralgia of extremities after receiving paroxetine tre...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31823da9a8

    authors: Yasui-Furukori N,Sato Y,Kato H,Kaneko S

    更新日期:2012-01-01 00:00:00

  • Kleptomania after head trauma: two case reports and combination treatment strategies.

    abstract::The purpose of this paper is to add to the growing number of reports about kleptomania occurring in relation to brain injury as well as to present the authors' findings regarding treatment strategies. The authors present two case reports of patients who developed the new onset of kleptomania after closed head trauma. ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/01.wnf.0000144042.66342.d3

    authors: Aizer A,Lowengrub K,Dannon PN

    更新日期:2004-09-01 00:00:00

  • Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.

    abstract::Fifty-six chronic schizophrenic patients were randomized into haloperidol decanoate (HD) or placebo groups for 48 weeks of double-blind treatment. The double-blind trial was preceded by a 15-week single-blind run-in period, during which all patients were treated with 60 mg of HD (approximately corresponding to 3.6 mg ...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Eklund K,Forsman A

    更新日期:1991-01-01 00:00:00

  • Obesity, genetics, and ponderal set point.

    abstract::A significant proportion of the interindividual variance in human fatness is attributable to genetic factors. This fact is indicated (inter alia) by studies of identical twins demonstrating that the degree of efficiency with which the body uses excess dietary energy for fat storage is, to a considerable extent, inheri...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Van Itallie TB

    更新日期:1988-01-01 00:00:00

  • Yi-gan san for treatment of charles bonnet syndrome (visual hallucination due to vision loss): an open-label study.

    abstract:BACKGROUND:Recent studies indicate that the traditional Japanese herbal medicine yi-gan san (YGS, yokukan-san in Japanese) may be safe and useful for treating behavioral and psychological symptoms in dementia, borderline personality disorder, neuroleptic-induced tardive dyskinesia, and treatment-resistant schizophrenia...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/WNF.0b013e318206785a

    authors: Miyaoka T,Furuya M,Kristian L,Wake R,Kawakami K,Nagahama M,Kawano K,Ieda M,Tsuchie K,Horiguchi J

    更新日期:2011-01-01 00:00:00

  • Pharmacokinetic comparison of two albendazole dosage regimens in patients with neurocysticercosis.

    abstract::To evaluate two different dosage regimens for albendazole (7.5 mg/kg twice a day or 5.0 mg/kg three times a day), a study was performed in 10 patients with a diagnosis of parenchymal brain cysticercosis. Each patient received both regimens sequentially according to a randomized, crossover design. Blood and urine sampl...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-199302000-00009

    authors: Sánchez M,Suástegui R,González-Esquivel D,Sotelo J,Jung H

    更新日期:1993-02-01 00:00:00

  • Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole.

    abstract::Patients with schizophrenia often experience comorbid obsessive-compulsive syndromes (OCSs). Within these patients, a significant subgroup developed secondary OCS during treatment with antiserotonergic, atypical antipsychotic agents such as clozapine. Although cognitive behavioral therapy and antiobsessive antidepress...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31819cc8e6

    authors: Englisch S,Esslinger C,Inta D,Weinbrenner A,Peus V,Gutschalk A,Schirmbeck F,Zink M

    更新日期:2009-07-01 00:00:00

  • Dopamine dysregulation syndrome and levodopa-induced dyskinesias in Parkinson disease: common consequences of anomalous forms of neural plasticity.

    abstract::Four to 10% of patients with Parkinson disease and chronically treated with levodopa undergo an addictionlike behavioral disturbance named dopamine dysregulation syndrome (DDS). This article suggests that patients with Parkinson disease could be especially prone to develop DDS due to the dopamine deficiency and the "p...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0B013E3181634EA6

    authors: Linazasoro G

    更新日期:2009-01-01 00:00:00

  • Reversible monoamine oxidase-A inhibitors in resistant major depression.

    abstract::Monoamine oxidase (MAO) inhibitors (MAOIs) provide effective alternative therapy for those patients with major depression who do not respond to tricyclic antidepressants or such related compounds as the selective serotonin reuptake inhibitors. This article reviews studies on the efficacy of both the classical MAOIs an...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Nolen WA,Hoencamp E,Bouvy PF,Haffmans PM

    更新日期:1993-01-01 00:00:00

  • Early addition of selegiline to L-Dopa treatment is beneficial for patients with Parkinson disease.

    abstract:OBJECTIVES:To evaluate the clinical outcome of Parkinson disease (PD) patients treated with selegiline (with L-Dopa/decarboxylase inhibitor) in the early stage of the disease in comparison with that of late-stage use of selegiline. METHODS:The study and the reference groups were extracted from a large database of the ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e3181bbf45c

    authors: Mizuno Y,Kondo T,Kuno S,Nomoto M,Yanagisawa N

    更新日期:2010-01-01 00:00:00

  • Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders.

    abstract::To investigate clinical aspects of the neutropenia induced by high-dose intravenous immunoglobulin therapy (IVIG) we performed serial hematology, including differentiation of white blood cells (WBC), before and after 22 instances of IVIG in 16 patients with neuroimmunologic disorders. WBC and neutrophils showed a sign...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200311000-00009

    authors: Matsuda M,Hosoda W,Sekijima Y,Hoshi K,Hashimoto T,Itoh S,Ikeda S

    更新日期:2003-11-01 00:00:00

  • Platelet supersensitivity to thrombin stimulation in depression: a possible mechanism for the association with cardiovascular mortality.

    abstract::The mortality risk associated with cardiovascular disease is significantly increased in patients with major depression and panic disorder. The mechanism of this phenomenon is unclear. Thrombin is responsible for platelet aggregation and shape change, and it plays a significant role in the development of thromboembolic...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-200007000-00002

    authors: Berk M,Plein H

    更新日期:2000-07-01 00:00:00

  • Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials.

    abstract::The extensive use of the Unified Parkinson's Disease Rating Scale (UPDRS) has revealed low interrater reliability in some items and redundancy in others. In view of these shortcomings, we have structured a new scale that includes a zero-to three-point scale for each item in the evaluation of PD. The mental axis includ...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Rabey JM,Bass H,Bonuccelli U,Brooks D,Klotz P,Korczyn AD,Kraus P,Martinez-Martin P,Morrish P,Van Sauten W,Van Hilten B

    更新日期:1997-08-01 00:00:00

  • Cyclosporine A neurotoxicity among bone marrow transplant recipients.

    abstract::Cyclosporine A (CsA) neurotoxicity is an iatrogenic disease with significant morbidity and occasional mortality. We retrospectively reviewed the cases of CsA neurotoxicity among bone marrow transplant recipients at our institution, and summarized the current literature on the subject. The neurologic presentation is va...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199903000-00001

    authors: Shah AK

    更新日期:1999-03-01 00:00:00

  • Astroglial cells: glucocorticoid target cells in the brain.

    abstract::Glutamine synthetase (GS), an enzyme localized in astroglial cells in the brain, is directly implicated in brain detoxification. An ontogenic study of GS activity was performed in homogenates from four distinct brain areas in comparison with the respective astrocytes obtained in primary cultures. GS was induced by hyd...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Tardy M,Rolland B,Fages C,Caldani M

    更新日期:1984-01-01 00:00:00

  • Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient.

    abstract:OBJECTIVE:Neuroleptic malignant syndrome was induced by aripiprazole in a 12 1/2-year-old boy. The patient had a history of reactive airway disease, pervasive developmental disorder, and learning disability. METHOD:The patient was interviewed and examined, and additional history was taken from the medical records. The...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/01.WNF.0000240941.13876.5E

    authors: Palakurthi HB,Parvin MM,Kaplan S

    更新日期:2007-01-01 00:00:00

  • Methylphenidate-Induced Enuresis: 3 Case Reports.

    abstract:ABSTRACT:Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children and adolescents. Methylphenidate (MPH) is one of the most widely used drugs in the treatment of ADHD. Enuresis can occur comorbidly with ADHD. However, enuresis is sometimes seen in patients with ADHD as an adve...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000422

    authors: Uzun N,Akinci MA,Karatoprak S

    更新日期:2021-01-01 00:00:00

  • Effects of terguride in patients with Huntington's disease.

    abstract::trans-Dihydrolisuride, a partial dopamine receptor agonist, was tested for its effects on chorea in a double-blind, crossover clinical study in 10 patients with Huntington's disease. In eight patients, a neurophysiological evaluation was also performed. No reduction in choreic movements or improvement in voluntary mov...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-198910000-00008

    authors: Stocchi F,Carta A,Berardelli A,Antonini A,Argenta M,Formica A,Agnoli A

    更新日期:1989-10-01 00:00:00

  • Levetiracetam is not effective for essential tremor.

    abstract:OBJECTIVE:To determine if levetiracetam is efficacious in the treatment of essential tremor. METHODS:Fifteen patients (3 women), aged 35 to 83 years, with essential tremor were studied in a double-blind, placebo-controlled crossover trial of levetiracetam. During the 2 treatment periods, levetiracetam or placebo was t...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/WNF.0b013E31807A32C6

    authors: Elble RJ,Lyons KE,Pahwa R

    更新日期:2007-11-01 00:00:00

  • The reversibility of "permanent" tardive dyskinesia.

    abstract::Neuroleptic-induced tardive dyskinesia (TD) that persists for 1 year or more following withdrawal of neuroleptics is usually said to be permanent. Early spontaneous remissions have been well described but most such remissions occurred within the first few months following neuroleptic withdrawal, and no published studi...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198406000-00006

    authors: Klawans HL,Tanner CM,Barr A

    更新日期:1984-01-01 00:00:00

  • Clinical usefulness of apomorphine in movement disorders.

    abstract::Apomorphine, the first dopamine agonist to be synthesized, has received a renewed interest in the last few years. This compound acts powerfully on D1 and D2 dopamine receptors and has the most complete pharmacological profile of all clinically available dopamine agonists. When given subcutaneously, apomorphine consist...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199406000-00004

    authors: Colosimo C,Merello M,Albanese A

    更新日期:1994-06-01 00:00:00

  • Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.

    abstract::A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia. No risk factors for rhabdomyolysis were found, but the calcium-dependent potassium efflux, normally responsible for membrane hyperpolarization and muscle refractoriness, was severely ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Koren W,Koren E,Nacasch N,Ehrenfeld M,Gur H

    更新日期:1998-07-01 00:00:00

  • One-Year Retention Study of Adjunctive Perampanel Treatment in Epilepsy Patients.

    abstract:OBJECTIVES:Perampanel is a recently introduced antiepileptic drug (AED) with a unique action mechanism of noncompetitive and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist. Because of delayed approval of perampanel in most Asian countries, there is limited information on the clinical usefulne...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000255

    authors: Kim DW,Oh J

    更新日期:2018-01-01 00:00:00

  • Nerve growth factor and Alzheimer's disease.

    abstract::Clinical trials with cholinergic agents suggest that cholinergic hypertrophy may be beneficial in the treatment of Alzheimer's disease (AD). Recent findings substantiate the view that nerve growth factor (NGF) selectively acts on cholinergic neurons. In adult rats and primates, intraventricular administration of nerve...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199114001-00008

    authors: Hefti F,Schneider LS

    更新日期:1991-01-01 00:00:00

  • Unusual case of levodopa-responsive camptocormia in a patient with negative dopamine transporter scan and normal DYT 5 gene.

    abstract:OBJECTIVE:To describe an unusual case of camptocormia responding to levodopa. METHODS:We present a case of camptocormia with a sustained excellent response to levodopa in a patient with negative dopamine transporter and no DYT 5 genetic mutations. RESULTS:We present a 52-year-old man with 2 years' history of progress...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000024

    authors: Oravivattanakul S,Abboud H,Fernandez H,Itin I

    更新日期:2014-03-01 00:00:00